GLPwatch
Papers (10588)
Page 159 of 177, ranked by citation count.
- Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.
- Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage.
- Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
- Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice.
- Cellular loci for cagrilintide action identified.
- Comparative Efficacy of Semaglutide versus Liraglutide on Weight Loss and Glycaemic Control.
- Liraglutide Enhances Cell Viability and Reduces Oxidative Stress in Hyperglycemic H9c2 Cardiomyocytes.
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
- Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.
- Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.
- Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.
- The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.
- [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
- Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
- GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
- Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.
- Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.
- Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.
- Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence.
- Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.
- Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review.
- Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model.
- A new indication for semaglutide (Wegovy).
- Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes.
- ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.
- Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies.
- New Indication for Weight Loss Drug Semaglutide.
- Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus.
- European Society of Cardiology 2018.
- Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?
- Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide.
- SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- [Obesity and type 2 diabetes mellitus (Update 2026)].
- Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.
- Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies.
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
- GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.
- Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.
- Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.
- In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.
- Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
- BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.
- Therapeutic potential of liraglutide in rheumatoid arthritis: Modulation of inflammation, apoptosis, and metabolic dysfunction in a rat model.
- [Dulaglutide and liraglutide compared].
- [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].
- Exenatide: excessive weight loss.
- Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.
- Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.
- [Basal insulin and liraglutide combined in a pen].
- Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-β overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage.
- Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study.
- [Nephroprotection in patients with diabetes mellitus].
- Single-dose pharmacokinetics of sublingual semaglutide in rats.
- Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro.
- Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation.
- Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.